Healthcare / BiotechnologyNasdaqCM
$1.15
+0.01 (+0.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-10.5M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1M
P/E
0.0x
↓EV/EBITDA
N/A
•ROE
-89.0%
↓Gross Margin
77.6%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1187.0%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $815371.0 · net income $-14.0M · FCF $-9.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $815371.00 | $815371.00 | $2.5M | $58465.00 | — | — |
| Net Income | $-14.0M | $-14.0M | $-58.7M | $-37.4M | $-13.4M | $-3.4M |
| EBITDA | $-13.3M | $-13.3M | $-57.6M | $-36.7M | $-13.4M | — |
| EPS | -828.00 | -828.00 | -21301.06 | -285570.18 | -151867.29 | -214200.00 |
| Gross Margin | 77.6% | 77.6% | 41.8% | -1927.9% | — | — |
| Operating Margin | -778.2% | -778.2% | -409.3% | -30526.4% | — | — |
| Net Margin | -1721.0% | -1721.0% | -2325.2% | -63986.5% | — | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.00 | 0.00 | 0.98 | -1.76 | — | — |
| Current Ratio | 1.41 | 1.41 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-9.7M | $-9.7M | $-10.5M | $-13.6M | $-8.7M | $-2.0M |
| Returns | ||||||
| ROE | -89.0% | -89.0% | -610.7% | 667.8% | -59.9% | -236.2% |
| Valuation | ||||||
| P/E | 0.00 | 0.00 | — | — | — | — |
| P/B | 0.00 | 0.00 | 0.99 | — | 0.78 | — |
| Growth & Yield | ||||||
| Revenue Growth | -67.7% | -67.7% | 4217.3% | — | — | — |
| EPS Growth | 96.1% | 96.1% | 92.5% | -88.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-99.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-21301.06 → -828.00
Residual
-99.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.